# | Sex/age a | Treatment b | Interval c | 11q23 phase d | TKI e | Treatment response | F/U from CML f | F/U from 11q23 g | Status at last F/U | |
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  | CCyR | MMR |  |  |  | ||
1 | F/64 | Imatinib | 17 | CP (1% blasts) | Yes | Yes | Yes | 68 | 50.2 | Alive |
2 | M/43 | IFNa, Imatinib, Dasatinib | 172 | AP (12% blasts) | Yes | No | No | 186 | 13.9 | Dead |
3 | M/67 | IFNa, Hydroxyurea | 17 | AP (12% blasts) | Yes | No | N/A | 33 | 16.6 | Dead |
4 | F/50 | IFNa | 7 | BP | Yes | No | No | 8 | 0.9 | Dead |
5 | M/70 | None | 0 | BP | Yes | Yes | Yes | 7 | 6.9 | Alive |
6 | M/31 | None | 0 | BP | Yes | NK | NK | 8 | 8 | Dead |
7 | F/21 | Hydroxyurea, Imatinib | 12 | BP | Yes | No | No | 21 | 9.5 | Dead |
8 | M/47 | Hydroxyurea, Imatinib | 13 | BP | Yes | No | No | 16 | 2.4 | Dead |
9 | M/59 | Hydroxyurea, IFNa, Imatinib | 13 | BP | No | Â | Â | 14 | 0.8 | Dead |
10 | F/50 | Hydroxyurea, IFNa | 12 | BP | No | Â | Â | 17 | 5.3 | Dead |
11 | M/48 | Nilotinib, Imatinib, Dasatinib | 32 | BP | No | Â | Â | 36 | 4.1 | Dead |